OUR JOURNEY

NEXT: PHASE IIA-READY

Therapeutic focus » The PharmNovo Journey

From safety to efficacy

HAVING FINALISED our first in man trials. Our aim is to establish efficacy through Phase IIA Proof of Concept studies in one or more patient populations starting in 2024.

Prior to 2020

Establishing the baseline

  • Founding PharmNovo
  • PN6047 discovered
  • Convincing pre-clinical efficacy data
  • Patent applications in major markets
2020-2023

Setting the scene

  • GMP compound production and process development
  • Toxicology studies to support clinical studies
  • Phase I - first in human trials
  • Secure patent protection in all major markets
2024-

Milestones

  • Establishing efficacy and defining path to market
  • Phase IIA PoC efficacy studies in one or more patient populations
  • Identification of VC/Pharma partner
  • Alignment of path to market with regulatory authorities, in particular EMA and FDA

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more